NDA 017858 · Sun Pharm Inds INC
An-Sulfur Colloid
Technetium Tc-99m Sulfur Colloid Kit · Injection, Oral
OrphanLast checked: Nov 20, 2026Latest source record: Dec 19, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Apr 17, 1978
Approved uses
4
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
6
3 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 13, 2024.
Technetium Tc 99m Sulfur Colloid Injection is indicated: In adults, to assist in the: localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma when used with a hand-held gamma counter. evaluation of peritoneo-venous (LeVeen) shunt patency. In adults and pediatric patients, for imaging: areas of functioning reticuloendothelial cells in the liver, spleen and bone marrow. studies of esophageal transit and, gastroesophageal reflux, and detection of pulmonary aspiration of gastric contents. Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated (1) : In adults, to assist in the: localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma when used with a hand-held gamma counter. evaluation of peritoneo-venous (LeVeen) shunt patency in adults. In adults and pediatric patients, for: imaging areas of functioning reticuloendothelial cells in the liver, spleen and bone marrow. studies of esophageal transit and gastroesophageal reflux, and detection of pulmonary aspiration of gastric contents.
Mechanism: Technetium Tc 99m decays by isomeric transition, emitting a photon that can be detected for imaging purposes. [see Description (11.1)] Following subcutaneous injection, Technetium Tc 99m Sulfur Colloid enters the lymphatic capillaries and is transported with lymph to lymph nodes. However, when there is massive nodal metastatic involvement, the normal transport to lymph nodes is lost because few normal cells remain in the node. [ see Dosage and Administration (2.4) ] Following intraperitoneal injection, Technetium Tc 99m Sulfur Colloid mixes with the peritoneal fluid; rate of clearance from...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 13, 2012 Supplement 35 · Efficacy OrphanLetterLabelReview
- Jul 22, 2011 Supplement 34 · Efficacy LabelLetter
- Sep 12, 1986 Supplement 15 · Efficacy
- Apr 17, 1978 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- AN-SULFUR COLLOID · TECHNETIUM TC-99M SULFUR COLLOID KIT N/A · SOLUTION, INJECTION, ORAL · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Sulfur Colloid Kit" as an intervention, any sponsor and status, largest first.
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT01677338 · 20 participants · Start Jul 2013 · Primary completion Jun 2014
Drug: 13C-uracil; 99mTc sulfur colloid · For: Dyspeptic Subjects
Sites: Orlando, Florida; Lebanon, New Hampshire
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea2
- sepsis2
- vomiting2
- blister1
- convulsion1
- flushing1
- hypersensitivity1
- injection site irritation1
- nosocomial infection1
- seizure1
- sensation of foreign body1
- sense of oppression1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2009 | 2 |
| 2014 | 2 |
| 2019 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Sun Pharm Inds INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.